These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35212134)

  • 1. Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern-based recognition.
    Das N; Dahiya M; Gupta R; Rai S; Singh S; Prajapati VK; Kumar L; Sharma A; Sahoo RK; Gogia A
    Cytometry B Clin Cytom; 2022 Jul; 102(4):292-302. PubMed ID: 35212134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients.
    Awasthi NP; Mishra S; Gupta G; Kumari S; Bajpayee A; Singh P; Husain N
    Indian J Pathol Microbiol; 2023; 66(2):295-300. PubMed ID: 37077071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters.
    Gupta S; Karandikar NJ; Ginader T; Bellizzi AM; Holman CJ
    Cytometry B Clin Cytom; 2018 May; 94(3):500-508. PubMed ID: 29316245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.
    Jeong TD; Park CJ; Shim H; Jang S; Chi HS; Yoon DH; Kim DY; Lee JH; Lee JH; Suh C; Lee KH
    Korean J Hematol; 2012 Dec; 47(4):260-6. PubMed ID: 23320004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma.
    Das N; Dahiya M; Gupta R; Kumar L; Sharma A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A
    Cytometry B Clin Cytom; 2022 May; 102(3):209-219. PubMed ID: 35389550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
    Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study.
    Limvorapitak W; Srisum-Ang T; Chimres C; Warnnissorn N; Kanitsap N
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e27-37. PubMed ID: 26796980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
    Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
    J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
    Tembhare PR; Yuan CM; Venzon D; Braylan R; Korde N; Manasanch E; Zuchlinsky D; Calvo K; Kurlander R; Bhutani M; Tageja N; Maric I; Mulquin M; Roschewski M; Kwok M; Liewehr D; Landgren O; Stetler-Stevenson M
    Leuk Res; 2014 Mar; 38(3):371-6. PubMed ID: 24462038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies.
    Tembhare PR; Ghogale S; Tauro W; Badrinath Y; Deshpande N; Kedia S; Cherian K; Patkar NV; Chatterjee G; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 May; 94(3):509-519. PubMed ID: 29316178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.
    Cannizzo E; Carulli G; Del Vecchio L; Ottaviano V; Bellio E; Zenari E; Azzarà A; Petrini M; Preffer F
    Am J Clin Pathol; 2012 Mar; 137(3):377-86. PubMed ID: 22338049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
    Rawstron AC; Orfao A; Beksac M; Bezdickova L; Brooimans RA; Bumbea H; Dalva K; Fuhler G; Gratama J; Hose D; Kovarova L; Lioznov M; Mateo G; Morilla R; Mylin AK; Omedé P; Pellat-Deceunynck C; Perez Andres M; Petrucci M; Ruggeri M; Rymkiewicz G; Schmitz A; Schreder M; Seynaeve C; Spacek M; de Tute RM; Van Valckenborgh E; Weston-Bell N; Owen RG; San Miguel JF; Sonneveld P; Johnsen HE;
    Haematologica; 2008 Mar; 93(3):431-8. PubMed ID: 18268286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
    Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
    Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
    Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
    Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
    Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR
    Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086
    [No Abstract]   [Full Text] [Related]  

  • 17. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
    Lin P; Owens R; Tricot G; Wilson CS
    Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry.
    Schouweiler KE; Karandikar NJ; Holman CJ
    Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
    McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
    Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.